AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$1.02 USD
-0.01 (-0.97%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $1.02 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
AN2 Therapeutics, Inc. (ANTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.00 | $3.00 | $1.00 | 94.17% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for AN2 Therapeutics, Inc. comes to $2.00. The forecasts range from a low of $1.00 to a high of $3.00. The average price target represents an increase of 94.17% from the last closing price of $1.03.
Analyst Price Targets (3 )
Broker Rating
AN2 Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 2.60 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, two are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ANTX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 0 | 0 |
ABR | 2.60 | 2.60 | 2.60 | 1.80 | 2.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Not Identified | Not Identified | Hold | Hold |
8/9/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Hold |
8/9/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
8/9/2024 | Evercore Partners | Liisa A Bayko | Hold | Strong Sell |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.60 |
ABR (Last week) | 2.60 |
# of Recs in ABR | 5 |
Average Target Price | $2.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 253 |
Current Quarter EPS Est: | -0.42 |
ANTX FAQs
AN2 Therapeutics, Inc. (ANTX) currently has an average brokerage recommendation (ABR) of 2.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for AN2 Therapeutics, Inc. (ANTX) is $2.00. The current on short-term price targets is based on 3 reports.
The forecasts for AN2 Therapeutics, Inc. (ANTX) range from a low of $1 to a high of $3. The average price target represents a increase of $96.08 from the last closing price of $1.02.
The current UPSIDE for AN2 Therapeutics, Inc. (ANTX) is 96.08%
Based on short-term price targets offered by three analysts, the average price target for AN2 Therapeutics, Inc. comes to $2.00. The forecasts range from a low of $1.00 to a high of $3.00. The average price target represents an increase of 94.17% from the last closing price of $1.03.